<DOC>
	<DOCNO>NCT00035360</DOCNO>
	<brief_summary>This randomize , double-blind , multicenter trial test 2 dos PEG-Intron , 1.0mcg/kg/week 3.0mcg/kg/week heavily treatment-experienced HIV-infected patient compare placebo . The study evaluate efficacy safety PEG-Intron add stable optimized background antiretroviral therapy patient population .</brief_summary>
	<brief_title>Phase III PEG-Intron HIV-infected Patients ( Study P00738 )</brief_title>
	<detailed_description>This study randomize 675 patient ( 225 3 arm ) either : PEG-Intron 1mcg ; 3mcg Placebo , 90 center worldwide . Each center enroll approximately 10 patient . Study drug add optimize background anti-retroviral therapy patient whose HIV RNA incompletely suppress therapy ( HIV RNA 400-50,000 copies/ML ) 2-6 month . A single dose reduction 50 % allow toxicity . An Interim Analysis conduct 50 % patient complete 24 week therapy . The study treatment phase 48 week monthly visit virologic virologic safety monitoring . The primary endpoint change HIV RNA baseline week assess efficacy . Durability response assess 48 week .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>HIV positive History virologic failure least 2 antiretroviral regimen include exposure least one NRTI , one NNRTI one PI HIV RNA &gt; 400 &lt; 50,000 copies/mL Laboratory parameter : platelet count ( 75,000u/L , hemoglobin &gt; 9gm/dl , absolute neutrophil count &gt; 1,000/uL , SGOT/SGPT &lt; 5xULN . Current ribavirin therapy Subjects recent diagnosis history moderate severe depression require ongoing psychiatric intervention Females childbearing potential breastfeeding , pregnant , use adequate birth control measure Concomitant use immunosuppressant cytotoxic agent History seizure disorder require use anticonvulsant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PEG-Intron</keyword>
	<keyword>treatment experience</keyword>
</DOC>